{"id":"https://openalex.org/W132288929","doi":null,"title":"Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?","display_name":"Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?","alternate_titles":[],"publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W132288929","mag":"132288929","pmid":"https://pubmed.ncbi.nlm.nih.gov/23735629"},"language":"en","primary_location":{"id":"mag:2608232863","doi":null,"is_oa":false,"landing_page_url":"https://primarycare.imedpub.com/are-prescribing-initiatives-readily-transferable-across-classes-the-case-of-generic-losartan-in-scotland.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764889781","display_name":"Quality in primary care","issn_l":"1479-1064","issn":["1479-1064","1479-1072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320266","host_organization_name":"Radcliffe Publishing","host_organization_lineage":["https://openalex.org/P4310320266","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Radcliffe Publishing","Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Quality in primary care","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W132288929"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067330259","display_name":"Marion Bennie","orcid":"https://orcid.org/0000-0002-4046-629X","observed_orcids":["https://orcid.org/0000-0002-4046-629X"]},"institutions":[{"id":"https://openalex.org/I181647926","display_name":"University of Strathclyde","ror":"https://ror.org/00n3w3b69","country_code":"GB","type":"education","lineage":["https://openalex.org/I181647926"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Marion Bennie","raw_affiliation_strings":["Strathclyde Institute for Pharmacy and Biomedical Sciences, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Strathclyde Institute for Pharmacy and Biomedical Sciences, UK","institution_ids":["https://openalex.org/I181647926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110209859","display_name":"Iain Bishop","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iain Bishop","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100656935","display_name":"Brian Godman","orcid":"https://orcid.org/0000-0001-6539-6972","observed_orcids":["https://orcid.org/0000-0001-6539-6972"]},"institutions":[{"id":"https://openalex.org/I181647926","display_name":"University of Strathclyde","ror":"https://ror.org/00n3w3b69","country_code":"GB","type":"education","lineage":["https://openalex.org/I181647926"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Brian Godman","raw_affiliation_strings":["Strathclyde Institute Of Pharmacy And Biomedical Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Strathclyde Institute Of Pharmacy And Biomedical Sciences","institution_ids":["https://openalex.org/I181647926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010513682","display_name":"Stephen Campbell","orcid":"https://orcid.org/0000-0002-2328-4136","observed_orcids":["https://orcid.org/0000-0002-2328-4136"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen Campbell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103452933","display_name":"Jamilette Miranda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamilette Miranda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025827617","display_name":"Alexander E. T. Finlayson","orcid":"https://orcid.org/0000-0002-2047-4671","observed_orcids":["https://orcid.org/0000-0002-2047-4671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexander E Finlayson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5005029886","display_name":"Lars Lennart Gustafsson","orcid":"https://orcid.org/0000-0002-0063-552X","observed_orcids":["https://orcid.org/0000-0002-0063-552X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lars L Gustafsson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.4876,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.97190235,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"21","issue":"1","first_page":"7","last_page":"15"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13555","display_name":"Healthcare cost, quality, practices","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/3600","display_name":"General Health Professions"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9769999980926514},{"id":"https://openalex.org/keywords/prescribing-patterns","display_name":"prescribing patterns","score":0.5090000033378601},{"id":"https://openalex.org/keywords/generic-substitution","display_name":"generic substitution","score":0.6129999756813049},{"id":"https://openalex.org/keywords/drug-tariff","display_name":"drug tariff","score":0.7590000033378601},{"id":"https://openalex.org/keywords/patent-expiration","display_name":"patent expiry","score":0.5059999823570251},{"id":"https://openalex.org/keywords/prescribing-incentives","display_name":"prescribing incentives","score":0.44999998807907104},{"id":"https://openalex.org/keywords/primary-care-prescribing","display_name":"primary care prescribing","score":0.6240000128746033},{"id":"https://openalex.org/keywords/defined-daily-doses","display_name":"defined daily doses","score":0.6700000166893005},{"id":"https://openalex.org/keywords/renin-angiotensin-system-inhibitors","display_name":"renin-angiotensin system inhibitors","score":0.7649999856948853},{"id":"https://openalex.org/keywords/pharmaceutical-expenditure","display_name":"pharmaceutical expenditure","score":0.42800000309944153},{"id":"https://openalex.org/keywords/scotland","display_name":"Scotland","score":0.7110000252723694}],"concepts":[{"id":"https://openalex.org/C2780288358","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan","level":4,"score":0.9570860862731934},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6252486109733582},{"id":"https://openalex.org/C2909209853","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan Potassium","level":5,"score":0.43708401918411255},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.43565672636032104},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39492130279541016},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.3216482996940613},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.2693915069103241},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20550960302352905},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08009523153305054}],"mesh":[{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010818","descriptor_name":"Practice Patterns, Physicians'","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D011320","descriptor_name":"Primary Health Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012606","descriptor_name":"Scotland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016568","descriptor_name":"Drugs, Generic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017723","descriptor_name":"Drug Utilization Review","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"mag:2608232863","doi":null,"is_oa":false,"landing_page_url":"https://primarycare.imedpub.com/are-prescribing-initiatives-readily-transferable-across-classes-the-case-of-generic-losartan-in-scotland.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764889781","display_name":"Quality in primary care","issn_l":"1479-1064","issn":["1479-1064","1479-1072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320266","host_organization_name":"Radcliffe Publishing","host_organization_lineage":["https://openalex.org/P4310320266","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Radcliffe Publishing","Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Quality in primary care","raw_type":null},{"id":"pmid:23735629","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23735629","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Quality in primary care","raw_type":"Journal Article"},{"id":"mag:132288929","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23735629","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9074000120162964}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1508421392","https://openalex.org/W1594644684","https://openalex.org/W1977563441","https://openalex.org/W1977752736","https://openalex.org/W1986829084","https://openalex.org/W1988716175","https://openalex.org/W2008860268","https://openalex.org/W2008878870","https://openalex.org/W2020762173","https://openalex.org/W2034447052","https://openalex.org/W2060535161","https://openalex.org/W2061570507","https://openalex.org/W2075841510","https://openalex.org/W2097619485","https://openalex.org/W2105138814","https://openalex.org/W2134726862","https://openalex.org/W2137704829","https://openalex.org/W2154755567","https://openalex.org/W2158409019","https://openalex.org/W2160675720","https://openalex.org/W2165926695","https://openalex.org/W2908737464","https://openalex.org/W4234874919"],"related_works":["https://openalex.org/W2034384891","https://openalex.org/W1963544199","https://openalex.org/W2020952273","https://openalex.org/W2034450421","https://openalex.org/W2149901050","https://openalex.org/W2160488641","https://openalex.org/W2047763542","https://openalex.org/W2801318107","https://openalex.org/W2122229852"],"abstract_inverted_index":{"BACKGROUND:":[0],"There":[1,157],"are":[2,86,222],"on-going":[3],"initiatives":[4,243],"in":[5,15,59,65,101,134,162],"Scotland":[6,153],"to":[7,19,113,224],"improve":[8],"the":[9,66,81,115,149,163,175,203],"quality":[10,242],"and":[11,39,53,80,140,193,244],"efficiency":[12],"of":[13,22,83,104,117,130,166,177,184,195,205,215,234],"prescribing":[14,21,33,37,226],"primary":[16],"care.":[17],"Activities":[18],"enhance":[20],"angiotensin-converting":[23],"enzyme":[24],"inhibitors":[25],"(ACEIs)":[26],"versus":[27,106,119],"angiotensin":[28],"receptor":[29],"blockers":[30],"(ARBs)":[31],"include":[32],"guidance,":[34],"guidelines,":[35],"benchmarking,":[36],"targets":[38],"financial":[40],"incentives.":[41],"These":[42],"measures":[43,221],"stabilised":[44],"reimbursed":[45],"expenditure":[46],"for":[47,182],"renin-angiotensin":[48],"inhibitor":[49],"drugs":[50],"between":[51,78],"2001":[52],"2007":[54],"despite":[55],"a":[56],"159%":[57],"increase":[58],"volumes.":[60],"Generic":[61],"losartan":[62,85,105,167,196,206],"was":[63,158,197,207],"included":[64],"Drug":[67],"Tariff":[68],"from":[69,148],"July":[70,110,142],"2010.":[71,111,143],"As":[72],"there":[73],"is":[74],"no":[75,159],"appreciable":[76],"difference":[77],"ARBs,":[79],"prices":[82,211],"generic":[84,118,178],"falling,":[87],"health":[88],"boards":[89],"should":[90],"be":[91,238],"actively":[92],"encouraging":[93],"its":[94],"prescribing.":[95],"AIM:":[96],"To":[97],"primarily":[98],"assess":[99,114],"changes":[100],"utilisation":[102,116,164],"patterns":[103],"other":[107,169,241,245],"ARBs":[108,170,186,246],"after":[109,141,174,189],"Second,":[112],"originator":[120],"losartan.":[121,179],"METHOD:":[122],"We":[123],"used":[124],"an":[125],"interrupted":[126],"time":[127],"series":[128],"analysis":[129],"ARB":[131],"utilisation,":[132],"measured":[133],"defined":[135],"daily":[136],"doses":[137],"(DDDs)":[138],"before":[139,172],"Utilisation":[144],"data":[145],"were":[146],"obtained":[147],"NHS":[150],"National":[151],"Services":[152],"Corporate":[154],"Warehouse.":[155],"RESULTS:":[156],"significant":[160],"change":[161,225],"pattern":[165],"or":[168,173,248],"combined":[171],"introduction":[176],"Losartan":[180],"accounted":[181],"32%":[183],"total":[185],"12":[187],"months":[188],"listing.":[190],"Between":[191],"98":[192],"99%":[194],"prescribed":[198],"generically.":[199],"In":[200],"March":[201],"2012,":[202],"price":[204],"88%":[208],"below":[209],"prepatent":[210],"with":[212,229],"potential":[213],"savings":[214,236],"?8m":[216],"per":[217],"year.":[218],"CONCLUSION:":[219],"Specific":[220],"needed":[223],"habits":[227],"especially":[228],"complex":[230],"messages.":[231],"The":[232],"cost":[233],"deriving":[235],"must":[237],"weighed":[239],"against":[240],"losing":[247,250],"shortly":[249],"their":[251],"patents.":[252]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W132288929","counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
